Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-18059
Thousands of yen (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending March 20276 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥12,458,551 thousand+3.9%
Operating profit¥175,282 thousand-9.3%
Ordinary income¥178,841 thousand-9.4%
Net income¥145,387 thousand+4.0%
Operating profit margin1.4 %
Selling, general and administrative expenses¥1,014,606 thousand
Full-year earnings forecast
Net Sales
¥25,200,000 thousand
Operating profit
¥600,000 thousand
Ordinary income
¥550,000 thousand
Profit attributable to owners of the parent
¥360,000 thousand
Earnings per share
¥128.75
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales49.4%
Operating profit29.2%
Ordinary income32.5%
Profit attributable to owners of the parent40.4%
Earnings per share40.3%
What the company explained in this material
New initiatives
- Reflecting the impact of newly opened nursery schools and stores in business performance
- Closure of a dispensing pharmacy due to road-widening construction scheduled for mid-November 2026
Key KPIsA metric the company considers important as a management benchmark.
- Number of prescriptions189,568 unitsYear on year against the same period last year+11,078 prescriptions
- Number of prescriptionsYear on year against the same period last year+5.3%
- Average prescription price¥20,668Year on year against the same period last year-¥359
- Enrollment9,300 peopleYear on year against the same period last year+126 people
- Occupancy rate of senior housing with support services98.2 %Year on year against the same period last year+4.2 percentage points
- Adult day-care users16,996 peopleYear on year against the same period last year+190 people
- Adult day-care utilization77 %Year on year against the same period last year+0.8 percentage points
Unit price and quantity metricsThese figures show sales broken down by price and volume.
- Number of prescriptions189,568 unitsYear on year against the same period last year+11,078 prescriptions
- Average prescription price¥20,668Year on year against the same period last year-¥359
Segment results
- PharmaceuticalsNet Sales¥5,004,374 thousand (YoY +3.2%)Segment profit¥167,094 thousand (YoY -17.5%)
- Childcare SupportNet Sales¥5,169,480 thousand (YoY +5.4%)Segment profit¥604,968 thousand (YoY +28.4%)
- Nursing careNet Sales¥1,780,045 thousand (YoY +1.2%)Segment profit¥-8,572 thousand
- Other (food)Net Sales¥504,650 thousand (YoY +5.9%)Segment profit¥3,116 thousand (YoY -53.9%)
Number of stores and locations
57 nursery schools (53 licensed and 4 certified). The pharmaceuticals business has 46 stores shown on the graph, comprising 26 pharmacies located near medical facilities and 20 pharmacies in medical malls. The number of store openings and closures during the period was Not disclosed.Annual Dividend
Annual dividend per share¥30
Interim Dividend¥13
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending March 2027 |
| Net Sales | ¥12,458,551 thousand (YoY +3.9%) |
| Operating profit | ¥175,282 thousand (YoY -9.3%) |
| Ordinary income | ¥178,841 thousand (YoY -9.4%) |
| Net income | ¥145,387 thousand (YoY +4.0%) |
| Operating profit margin | 1.4 % |
| Selling, general and administrative expenses | ¥1,014,606 thousand |
| Full-year earnings forecast | Net Sales ¥25,200,000 thousand / Operating profit ¥600,000 thousand / Ordinary income ¥550,000 thousand / Profit attributable to owners of the parent ¥360,000 thousand / Earnings per share ¥128.75 |
| Progress against full-year forecast | Net Sales 49.4% / Operating profit 29.2% / Ordinary income 32.5% / Profit attributable to owners of the parent 40.4% / Earnings per share 40.3% |
| Segment results | Segment Pharmaceuticals / Net Sales ¥5,004,374 thousand (YoY +3.2%) / Segment profit ¥167,094 thousand (YoY -17.5%), Segment Childcare Support / Net Sales ¥5,169,480 thousand (YoY +5.4%) / Segment profit ¥604,968 thousand (YoY +28.4%), Segment Nursing care / Net Sales ¥1,780,045 thousand (YoY +1.2%) / Segment profit ¥-8,572 thousand, Segment Other (food) / Net Sales ¥504,650 thousand (YoY +5.9%) / Segment profit ¥3,116 thousand (YoY -53.9%) |
| Key KPIs | Indicator name Number of prescriptions / Value 189,568 units / Year on year against the same period last year +11,078 prescriptions, Indicator name Number of prescriptions / Value Not disclosed / Year on year against the same period last year +5.3%, Indicator name Average prescription price / Value ¥20,668 / Year on year against the same period last year -¥359, Indicator name Enrollment / Value 9,300 people / Year on year against the same period last year +126 people, Indicator name Occupancy rate of senior housing with support services / Value 98.2 % / Year on year against the same period last year +4.2 percentage points, Indicator name Adult day-care users / Value 16,996 people / Year on year against the same period last year +190 people, Indicator name Adult day-care utilization / Value 77 % / Year on year against the same period last year +0.8 percentage points |
| Unit price and quantity metrics | Indicator name Number of prescriptions / Value 189,568 units / Year on year against the same period last year +11,078 prescriptions, Indicator name Average prescription price / Value ¥20,668 / Year on year against the same period last year -¥359 |
| Number of stores and locations | 57 nursery schools (53 licensed and 4 certified). The pharmaceuticals business has 46 stores shown on the graph, comprising 26 pharmacies located near medical facilities and 20 pharmacies in medical malls. The number of store openings and closures during the period was Not disclosed. |
| Annual Dividend | Annual dividend per share ¥30 / Interim Dividend ¥13 / Year-end dividend Not disclosed |
| New initiatives | Reflecting the impact of newly opened nursery schools and stores in business performance, Closure of a dispensing pharmacy due to road-widening construction scheduled for mid-November 2026 |
Items this document does not state (15)
Gross Profit MarginResults for the three months of the current quarterSelf-assessment against the planBreakdown of Factors Affecting the ChangeNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue was supported by an increase in prescription volume from new store openings, higher prescription unit prices due to prescriptions for high-priced pharmaceuticals, an increase in the number of children attending nursery schools, and upward revisions to regulated prices. Operating profit was affected by higher fixed costs, primarily personnel expenses, due to revisions to dispensing fees, soaring procurement prices, and wage increases aimed at securing personnel and improving compensation. At the same time, the company recorded relocation compensation and other items related to road-widening construction as extraordinary gains.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.